BPG is committed to discovery and dissemination of knowledge
Articles Published Processes
2/24/2023 1:35:50 PM | Browse: 161 | Download: 280
Publication Name World Journal of Hepatology
Manuscript ID 80133
Country China
Received
2022-09-18 09:51
Peer-Review Started
2022-09-18 09:53
To Make the First Decision
Return for Revision
2022-10-31 01:18
Revised
2022-11-13 05:39
Second Decision
2023-01-20 03:30
Accepted by Journal Editor-in-Chief
Accepted by Company Editor-in-Chief
2023-01-23 15:26
Articles in Press
2023-01-23 15:26
Publication Fee Transferred
Edit the Manuscript by Language Editor
2023-01-09 03:55
Typeset the Manuscript
2023-01-28 08:19
Publish the Manuscript Online
2023-02-24 13:35
ISSN 1948-5182 (online)
Open Access This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/Licenses/by-nc/4.0/
Copyright © The Author(s) 2023. Published by Baishideng Publishing Group Inc. All rights reserved.
Article Reprints For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
Permissions For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
Publisher Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
Website http://www.wjgnet.com
Category Oncology
Manuscript Type Review
Article Title Current status and prospect of treatments for recurrent hepatocellular carcinoma
Manuscript Source Invited Manuscript
All Author List Yu-Qing Yang, Zhen-Yu Wen, Xiao-Yan Liu, Zhen-Hu Ma, Yan-E Liu, Xue-Ying Cao, Li Hou and Hui Xie
ORCID
Author(s) ORCID Number
Yu-Qing Yang http://orcid.org/0000-0002-8374-8617
Zhen-Yu Wen http://orcid.org/0000-0002-5008-7197
Xiao-Yan Liu http://orcid.org/0000-0002-6604-7253
Hui Xie http://orcid.org/0000-0003-4322-7267
Funding Agency and Grant Number
Corresponding Author Hui Xie, MD, Chief Doctor, Department of Interventional Therapy, 302 Hospital of People’s Liberation Army, No. 100, Western 4th Ring Middle Road, Fengtai District, Beijing 100039, China. xh302jr@126.com
Key Words Review; Recurrence; Hepatocellular carcinoma; Hepatectomy; Liver transplantation; Transcatheter arterial chemoembolization
Core Tip The current rate of recurrence after initial hepatocellular carcinoma treatment remains unsatisfactory. Repeat hepatectomy and salvage liver transplantation are the preferred options for patients who meet the criteria. However, for patients whose clinical situation do not allow these treatments, non-surgical treatment can also provide survival benefits. Additionally, adjuvant treatment strategies to prevent recurrence and proper surveillance are effective tools to improve overall patient survival. This review summarizes the existing literature to help guide clinical decision-making and provide directions for further research.
Publish Date 2023-02-24 13:35
Citation Yang YQ, Wen ZY, Liu XY, Ma ZH, Liu YE, Cao XY, Hou L, Hui X. Current status and prospect of treatments for recurrent hepatocellular carcinoma. World J Hepatol 2023; 15(2): 129-150
URL https://www.wjgnet.com/1948-5182/full/v15/i2/129.htm
DOI https://dx.doi.org/10.4254/wjh.v15.i2.129
Full Article (PDF) WJH-15-129.pdf
Full Article (Word) WJH-15-129.docx
Manuscript File 80133_Auto_Edited-LM.docx
Answering Reviewers 80133-Answering reviewers.pdf
Audio Core Tip 80133-Audio core tip.aac
Conflict-of-Interest Disclosure Form 80133-Conflict-of-interest statement.pdf
Copyright License Agreement 80133-Copyright license agreement.pdf
Non-Native Speakers of English Editing Certificate 80133-Language certificate.pdf
Peer-review Report 80133-Peer-review(s).pdf
Scientific Misconduct Check 80133-Bing-Wang JJ-2.png
Scientific Editor Work List 80133-Scientific editor work list.pdf